Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role

Immunic Inc

Immunic Inc CEO Dr Daniel Vitt joins Proactive's Stephen Gunnion on the International Day of Immunology to discuss the broad and crucial role of immunology in human health. Vitt said immunology encompasses immune responses against pathogens like viruses, including the coronavirus, and also plays a significant role in combating cancer. He highlighted the importance of the immune system in managing and preventing autoimmune diseases, where the body mistakenly attacks its own cells, leading to various conditions. Focusing on Immunic's efforts, Vitt detailed their drug development pipeline, particularly in addressing chronic inflammatory and autoimmune diseases such as multiple sclerosis, ulcerative colitis, Crohn's disease, and celiac disease. He spotlighted multiple sclerosis, with ongoing phase three studies in its relapsing form and a phase two study, named the CALLIPER trial, for its progressive form. The latter holds particular promise as it targets an area with currently no available treatments. For celiac disease, Vitt reported promising results from a phase one B proof-of-concept study that showed positive data across various metrics, including histology and biomarker levels. Plans are underway for further phase two studies in celiac disease and potentially other indications. Vitt also shared his personal journey from chemistry to immunology, driven by the potential to develop drugs that address significant medical needs. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

April 29, 2024 11:11 AM Eastern Daylight Time

Video

New Standard of Care? IceCure Submits Final ICE3 Data To FDA, Minimally Invasive Cryoablation Shows Similar 5-year Recurrence Outcomes To Surgery With Hormone Therapy

Benzinga

By Meg Flippin, Benzinga IceCure Medical Ltd. (NASDAQ: ICCM), the Israeli medical device developer of ProSense®, an advanced liquid-nitrogen-based cryoablation therapy that destroys tumors (benign and cancerous) by freezing them, is one step closer to getting U.S. Food and Drug Administration approval to market ProSense® to treat patients with early-stage T1 invasive breast cancer with cryoablation and adjuvant hormone therapy. IceCure just reported final clinical trial results of 100% patient and physician satisfaction with the minimally invasive procedure. At the 5-year follow-up evaluation, 96.3% of the subgroup of patients treated with ProSense® cryoablation, followed by hormone therapy, were estimated to be free from local recurrence Earlier in April, the company submitted its final data to the FDA which included five-year follow-up data from its ICE3 study, a sub-analysis of the ICE3 results compared to studies that evaluated the risk of recurrence in patients with low-risk Luminal A breast cancer who were treated with lumpectomy surgery and received hormone therapy and real-world data from the use of ProSense® globally, including post-market commercial use as well as data from independent third-party studies. ProSense®, which received the FDA's Breakthrough Device Designation, is already cleared for use in the U.S. for several other indications, including treating benign tumors of the breast and tumors in the kidney and liver. Positive Topline Results IceCure’s ICE3 study was the largest controlled multicenter clinical trial ever performed for liquid nitrogen (LN2) based cryoablation of low-risk, early-stage malignant breast tumors. The five-year recurrence-free rates from the study, which evaluated IceCure's minimally invasive 20-to-40-minute outpatient cryoablation procedure, were in line with expectations and showed similar outcomes to lumpectomy, the current standard of care for early-stage breast cancer patients, which is breast surgery that requires an operating room and hospital stay. In the ICE3 study, 96.39% of patients (187 out of 194 patients) were local recurrence-free with no significant device-related adverse events or complications reported. A comparison of this result from the ICE3 study shows similar outcomes in five-year recurrence rates compared to patients in other studies who were treated with lumpectomy followed by hormone therapy. The LUMINA study reported a 97.7% recurrence-free rate at five-year follow-up and the PRISMA meta-study, which included Lumina, reported a 97.19% recurrence-free rate at five-year follow-up. ICE3 results are also in line with data from real-world use of ProSense® by third parties in territories where IceCure's cryoablation system is used to treat early-stage breast cancer. In the final ICE3 analysis, no significant device-related adverse events or complications were reported, and all patients and physicians reported satisfaction with the ProSense® procedure, the company said. That means 100% of physicians and patients were happy with the treatments they received. Dr. Richard Fine, ICE3’s lead investigator, presented final data from the ICE3 study at the American Society of Breast Surgeons 25th Annual Meeting, where he commented, "Cryoablation is a safe, minimally invasive ablative procedure with acceptably low five-year same breast recurrence similar to that of lumpectomy for similar patient populations, with the benefit of being an office-based, nonsurgical treatment. Further study within a clinical trial or registry is needed to confirm cryoablation as a viable alternative to surgical excision in the appropriately selected patients.” Dr. Fine’s presentation, which received the conference’s Scientific Impact Award, was well received by breast surgeons who are constantly looking for treatments that are minimally invasive and effective. A New Way To Treat An Old Problem What makes cryoablation so attractive to freeze and destroy tumors is that it is minimally invasive, has little pain associated with it and thanks to an ultrasound or computerized tomography can accurately destroy diseased tissue within the tumor zone. Cryoablation also costs less than a lumpectomy and reduces the risk of follow-up surgery. With a lumpectomy, the re-excision rate is between 14-21%. IceCure’s ProSense® has the potential to become a new standard of care treatment for women with early-stage T1 invasive breast cancer, marking a major improvement to the care available today. Some researchers have even called cryoablation the “ ultimate esthetic solution for breast cancer ” because it reduces the need for pre-emptive or corrective surgical procedures to maintain or restore breast volume, contour and symmetry. "Initial reimbursement codes are already in place and our U.S. marketing and commercial team is ready, as we await the FDA's response. Driven by favorable healthcare economics combined with patient satisfaction and demand, we expect rapid adoption pending FDA granting the DeNovo Classification Request for Marketing Approval," stated IceCure CEO Eyal Shamir. With Reimbursement In Place, IceCure Is Ready To Go With the final data submitted, IceCure is ready to go once the FDA gives it the green light. The company received what it said was the first Medicare coverage approval of a cryoablation procedure for breast cancer. The Centers for Medicare & Medicaid Services (CMS) set the reimbursement payment at about $3,400 for the facility alone. Additional coverage, including payment for the physician, is expected upon establishment of the permanent CPT Category I code, which is conditioned on factors including the company's receipt of FDA marketing authorization of ProSense® for breast cancer. Having that reimbursement should enhance the usage of the ProSense® system. Nearly 300,000 women are diagnosed with invasive breast cancer yearly, and the majority have to undergo invasive treatments and deal with follow-up surgeries in the quest to live cancer-free. IceCure is changing that by freezing tumors to destroy them. IceCure seems poised to do exactly what it set out to do: provide women with an alternative minimally invasive treatment option. Featured photo by Angiola Harry on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

April 29, 2024 08:20 AM Eastern Daylight Time

Image

AI Frontiers in Healthcare: Revolutionizing Medicine at the 2024 1ArtificialIntelligence Global Conference

1BusinessWorld

As the healthcare sector undergoes a technological transformation, artificial intelligence (AI) is at the forefront, driving significant advancements. The 1ArtificialIntelligence | 2024 Global AI Conference will delve into these developments during its standout session, " Breaking New Ground: How AI and Tech Startups Are Revolutionizing the Digital Health Landscape. " Scheduled for May 9, this pivotal discussion promises to highlight the innovative role of AI in reshaping healthcare delivery and management. Moderated by Sally Ann Frank, Worldwide Lead for Health & Life Sciences, Microsoft for Startups, this panel brings together industry luminaries who are pioneering the integration of AI into healthcare. The session features: - Sally Ann Frank, WW Lead, Health & Life Sciences, Microsoft for Startups - Stead Burwell, Founder & CEO, Outbound AI - Lana Feng, Co-founder and CEO, Huma.Al - Andrew Gostine, CEO, Artisight - Ankur Teredesai, CEO, CueZen These experts are set to discuss the transformative impact of AI across various aspects of healthcare: - AI-Driven Diagnostics and Personalized Treatment: The panel will explore how AI is enhancing diagnostic accuracy and enabling personalized treatment plans that are tailored to individual patient needs. - Operational Efficiency: Insights will be shared on how AI is streamlining operations within healthcare facilities, from administrative processes to patient care, reducing costs and improving service delivery. - Ethical and Regulatory Frameworks: As AI becomes more entrenched in healthcare, the panelists will tackle the ethical considerations and regulatory challenges that need to be navigated to ensure responsible deployment of AI technologies. The discussion is not just about what AI is currently achieving but also about its future potential. The panelists will provide forecasts on emerging technologies, anticipated regulatory developments, and the long-term implications of AI in healthcare. This session will serve as a comprehensive guide for healthcare professionals, technology innovators, and policymakers interested in the intersection of AI and healthcare. For those looking to stay at the cutting edge of healthcare innovation, the "Breaking New Ground" session at the 1ArtificialIntelligence | 2024 Global AI Conference is an unmissable event. It offers a unique opportunity to hear from the trailblazers who are not only navigating the challenges of AI integration but are also setting the stage for the next generation of healthcare solutions. Contact Details Media Enquiries +1 212-220-6677 info@1businessworld.com Company Website https://1businessworld.com

April 28, 2024 03:17 PM Eastern Daylight Time

Image

Over 200 passionate programmers participated in The Bucharest Hackathon 2024, and the total prizes exceeded 50,000 dollars

STORM Partners

https://we.tl/t-lk7ZTXr33k Bucharest, 25th of April 2024: On April 14th, the Odeon Theater hosted the second edition of The Bucharest Hackathon, the first hackathon in Romania dedicated to enthusiasts of new technologies. The competition brought together over 200 amateur and senior programmers, both Romanian and foreign, who came from Bucharest as well as from other cities in the country, such as Cluj, Brasov, or Craiova. For 24 hours, they coded and competed in developing software projects that tested the limits of modern technologies. The top three teams won the grand prize of a total value of $30,000, but 25 teams were also selected to receive special prizes from the partners. For the final competition, 35 teams were selected. “ The Bucharest Hackathon is attracting more and more participants. I was impressed by the level of competence of the teams and projects and their achievements in only 24 hours. The jury members, most of whom have international experience, appreciated the location and organization, stating that they felt like they were at a hackathon in Silicon Valley. Genezio was chosen by more than half of the teams to implement their solution. ” Andrei Pitis, CEO & Co-founder of Genezio. “ From the moment we saw the first registrations for the event, we realized that we were going to have a completely different edition: an iconic location, much bolder ideas, much more creative solutions, but also a considerable effort - and so it was. The Bucharest Hackathon was truly an emotional roller-coaster: from the trust in the colleagues on our team to the transformation of an idea into a product, and to the decisive moment when you find out if you are among the winners,” said Flavian Manea, CEO and co-founder of Bware Labs. “At MultiversX, we are proud to support innovation and entrepreneurship in our tech community. The partnership with The Bucharest Hackathon underlines our commitment to the future of technology and innovation in Romania. We are excited to see such creative ideas turned into reality and provide the necessary support for these projects to become successful startups”, Daniel Serb, VP of Business Development of MultiversX. Each of the three winning teams received prizes worth over $10,000, as well as Amazon vouchers worth $15,000, while the teams that won special prizes from the partners received $20,000 in vouchers on the Blast platform, developed by Bware Labs, $10,000 in Genezio vouchers, two startup support prizes from MultiversX, a special prize from Google: Google Nest Hub (2nd Gen) smart speakers, an innovation prize from PiSquared worth $2,500 in vouchers and $2,000 in consulting vouchers from Astrarizon. Fork_Exec, Salty, and Awesome Hackers are this year's winning teams at The Bucharest Hackathon This year’s grand prize of $5,000 was won by the Fork_Exec team, made up of Dejanu Alexandru, Opri Cezar, and Dumitru Iulia. Fork_Exec developed a software solution based on speech recognition and artificial intelligence technologies that allows programmers to automate parts of coding based on voice commands. Second place, worth $3,000, went to the Salty team, composed of Kerimberdi Agayev Kaibov Merdan and Cihan Ilhan. They proposed an application for high school students to receive guidance on complex math problems. The application takes the user’s handwriting and, combining OpenAI and AWS Cloud technologies provides the answer to the problem almost instantly. The third prize, of $2,000, was won by the programmers from the Awesome Hackers team, namely Puiu Răzvan, Ene Cosmina, and Manea Lucas. Awesome Hackers created a neural data collection platform designed to help improve cognitive function and focus. In addition, two of the participating teams will receive support from MultiversX so that their ideas can reach the startup stage (Awesome Hackers and Mental Regression). Among the special prize winners is also the Wildcard team, who received a Nest Hub 2nd Generation from Google. The jury was made up of tech experts, IT entrepreneurs, and top executives from the companies: Genezio, Bware Labs, MultiversX, Google, Stripe, PiSquared, XOXNO, and Amazon Web Services. For this edition, the main partners Genezio and Bware Labs, the co-founding companies of The Bucharest Hackathon project, were joined by the Romanian blockchain company MultiversX. Among the partners of the second edition of The Bucharest Hackathon are the companies Stripe, PiSquared, XOXNO, Google, Amazon Web Services, Astrarizon, and xExchange. The event was sponsored by Orange Romania, AQUA Carpatica, Blue Romania, Domeniile Averești, Komoder Romania, Nespresso Professional, and Good Routine by SECOM, with media and communication partners Republica, Innovation Labs, ETH Bucharest, Caracteristic PR, KCD Romania, and the Student League Electronics. About The Bucharest Hackathon The Bucharest Hackathon is a 24-hour competition dedicated to programmers and enthusiasts of modern technologies, such as AI, Dev Tools, blockchain, and others. Although initially dedicated to those in Bucharest, the event welcomed programmers from other cities or countries in both editions. The event was founded by Bware Labs and Genezio in 2023 to provide enthusiasts of modern technologies with the space, resources, and challenges they need to develop themselves and test both their limits and those of new technologies. About MultiversX MultiversX is a highly scalable, secure, and decentralized blockchain network built from first principles, to solve the two fundamental problems critical for widespread, global adoption: a transition from dialup to broadband, and a significant UX paradigm shift. Media Contact: Dan Voicu, Head of Communications dan.voicu@multiversx.com Distributed by STORM Partners. Contact Adrian Bono for interviews and quotes - adrian.bono@storm.partners or telegram @STORMPartners Contact Details MultiversX Dan Voicu, Head of Communications dan.voicu@multiversx.com Company Website https://multiversx.com/

April 25, 2024 11:07 AM Eastern Daylight Time

Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health

Petros Pharmaceuticals Inc

Petros Pharmaceuticals CEO Fady Boctor joined Steve Darling from Proactive to share exciting developments with Proactive, highlighting a new collaboration with Lemonaid Health, a prominent telemedicine provider and subsidiary of 23andMe. Through this collaboration, Lemonaid Health's telehealth platform will offer prescription STENDRA® (avanafil) in all strengths, expanding distribution and enhancing access for patients. Lemonaid Health's extensive reach, having treated over 200,000 patients with erectile dysfunction (ED) to date, positions Petros to serve a broader patient base across the United States effectively. In addition to the collaboration with Lemonaid Health, Boctor discussed the positive results of an initial cohort in Petros' self-selection study. This study compares the use of a Drug Facts Label (DFL) alone to a combination of DFL with a web app. The preliminary results suggest that while the DFL-alone approach may be insufficient for self-selection, the combination with the proposed technology significantly improves outcomes. This study serves as a precursor to Petros' pivotal Phase 2 study, initiated earlier this month, which aims to provide compelling evidence to the FDA. The pivotal study is designed to demonstrate that users can determine the appropriateness of STENDRA® (avanafil) without the need for a physician and prescription. These developments underscore Petros Pharmaceuticals' commitment to leveraging innovative solutions to improve patient access to essential medications and streamline healthcare delivery processes. Contact Details Proactive North America Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com

April 25, 2024 10:20 AM Eastern Daylight Time

Video

Hoag Health System Selects PathAI and the AISight Image Management System to Support the Transition To Digital and AI-enabled Pathology

PathAI

PathAI, a leading precision pathology company, today announced that Hoag Health System, the leading health system in the southern California region, will adopt the AISight Image Management System (IMS) as their primary platform, powering their transition to digital pathology. The transition from analog, glass-slide-based pathology to digital pathology continues to accelerate across anatomic pathology, globally. This transition is in part driven by the availability of AI pathology tools that harness machine learning (ML) algorithms to augment and assist the pathologist interpretation. “The transition to digital pathology will unlock dramatic improvements in how care is provided to Hoag’s patients. By utilizing the most advanced image management system on the market with embedded algorithms, we expect to be able to deliver faster turnaround times to our physicians, more accurate and reproducible pathologist assessments, and expand our understanding of how biomarkers can drive optimal care decisions,” said Dr. Michael Brant-Zawadzki, MD, FACR, Hoag Vice President, Research Administration, CATALiST and Addiction. AISight 1 is a cloud-native intelligent enterprise workflow solution that is used by the world's leading laboratories and research centers to power their digital pathology workflows and AI applications. It serves as a central hub for case management, image management, and best-in-class artificial intelligence tools from PathAI and third-party partners, to enable a broad spectrum of histopathology use cases. “Together with our partners, we will continue to pursue our vision to improve patient outcomes with AI-powered technology,” said Eric Walk, MD, FCAP, Chief Medical Officer, PathAI. “We are excited to partner with forward-thinking industry leaders like Hoag who embrace the science of what machine learning algorithms can offer healthcare professionals and how those learnings can augment and empower the important work of pathologists.” According to Dr. John Cupp, MD, Director of Digital Pathology, Hoag Health System and PathAI Advisor, “Hoag is particularly excited to utilize PathAI’s ArtifactDetect algorithm that can improve pathology review, specifically to address pre-analytical factors that typically would delay pathologist review, as well as applying PathAI’s quantitative IHC scoring algorithms to support complex interpretation in PDL1 and HER2.” Importantly, PathAI will collaborate with Hoag and their laboratory information system (LIS) provider to build a bi-directional integration between AISight and their Epic Beaker LIS instance to ensure a fully integrated pathologist experience. “Computational pathology promises to unlock great potential for predictive biomarkers for patients with cancer,” said Dr. David R. Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute. “This is an exciting next step in Hoag’s digital transformation as we continue to look ahead towards healthcare innovations that offer continual advancements in patient care, treatment efficacy, and overall public health outcomes.” 1 AISight is For Research Use Only. Not for use in diagnostic procedures. About Hoag Hoag is a nonprofit, regional health care delivery system in Orange County, California. Delivering world-class, comprehensive, personalized care, Hoag consists of 1,800 top physicians, 16 urgent care facilities, 11 health & wellness centers, and two award-winning hospitals. Hoag offers a comprehensive blend of health care services that includes seven institutes providing specialized services in the following areas: cancer, digestive health, heart and vascular, neurosciences, spine, women’s health, and orthopedics through Hoag’s affiliate, Hoag Orthopedic Institute, which consists of an orthopedic hospital and four ambulatory surgical centers. Hoag is the highest ranked hospital in Orange County by U.S. News & World Report and the only OC hospital ranked in the Top 10 in California, as well as a designated Magnet® hospital by the American Nurses Credentialing Center (ANCC). For more information, visit hoag.org. About PathAI PathAI is the leading precision pathology company providing software and AI-enabled solutions to all pathologist stakeholders including laboratories, research institutions, and the biopharma industry. Developed with the input of hundreds of pathologists, PathAI’s digital pathology Image Management System, AISight, is the solution of choice for laboratories transitioning to digital workflows. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

April 25, 2024 10:00 AM Eastern Daylight Time

ECLYPSES USHERS IN NEW ERA OF CYBERSECURITY ASSURANCE WITH FIPS 140-3 VALIDATION OF ITS CRYPTOGRAPHIC LIBRARY

Eclypses Inc.

Eclypses, a leader in end-point data protection, today announced that it has successfully secured the Federal Information Processing Standard 140-3 (FIPS 140-3) validation. The Eclypses Cryptographic Library (ECL), which acts as a key component inside its Secure MTE Technology, successfully passed a series of tests conducted by an independent NIST-accredited laboratory. Eclypses is committed to providing its global customers with the most stringently reviewed technology to ensure their users’ data is protected. Secure MTE technology protects data at the application level, and provides endpoint verification, adhering to zero trust principles. "Customers operating in a world of exponential and ever-changing cyber threats need to have trust that their enterprise and customer data is protected,” said David Gomes, chief executive officer, Eclypses. “Attaining FIPS 140-3 certification acknowledges Eclypses' relentless pursuit of excellence in data security. This certification validates our commitment to robust security protocols and paves the way for enhanced trust and reliability for our customers and partners." About FIPS 140-3 Seen as the gold standard in data security, FIPS 140-3 validation proves that Eclypses’ Cryptographic Library effectively and consistently helps the Secure MTE Technology safeguard user data, ensuring that bad actors cannot access valuable information at any point during the data transmission process. FIPS 140-3 is a U.S. government computer security standard used to approve cryptographic modules and covers a wide range of potential applications. With this validation from a National Institute of Standards and Technology (NIST) approved testing laboratory, Eclypses Cryptographic Library (ECL) is now validated. ECL houses all cryptographic algorithms used by Eclypses’ patented Secure MTE technology. Secure MTE provides true end-to-end payload protection through every aspect of a network, regardless of the configuration, and ensures that in the event of a breach, attackers cannot use the data to cause harm. This technology is an added layer of security at a low latency, complementing existing cyber security protocols with real-time speeds. FIPS 140-3 validation gives Eclypses clients confidence that its technology is built upon the highest levels of trust and reliability. “This validation signals a company has completed a strict review process and received validation from one of the most highly regarded security standards bodies in the world,” said Jefferson Dance, chief innovation officer, Eclypses. “With the FIPS 140-3 validation, Eclypses can continue to deliver data security for its finance, healthcare, retail, and critical infrastructure clients.” In order to achieve FIPS 140-3 validation, cryptographic modules are subject to testing by NVLAP-accredited Cryptographic and Security Testing laboratories. The validation for Eclypses was performed by Penumbra Security, Inc. About Eclypses Eclypses sets the new standard for protecting the world’s most sensitive enterprise and customer data. Secure MTE® Technology delivers a transformative cyber security solution by replacing actual data with instantly obsolete, meaningless random streams of values. Even as threat vectors increase and network breaches proliferate, sensitive data is protected for its intended recipients and use. Eclypses was named Best Cybersecurity Solution in the FTF News Technology Innovations Awards in 2022 and 2023. For more information, please visit www.eclypses.com. Contact Details Racepoint Global Anna Halstead +1 617-624-3212 eclypses@racepointglobal.com

April 25, 2024 09:03 AM Eastern Daylight Time

MariMed closes acquisition of a dispensary in Illinois marking the company’s 5th in that state

MariMed Inc

MariMed CEO Jon Levine joined Steve Darling from Proactive to to share the Company’s significant developments, including its recent of Allgreens Dispensary, LLC, which closed on April 9, 2024. The acquisition enabled the Company to operate its 5th Thrive-branded dispensary in Illinois. It followed the recent opening of the Company’s processing facility in Mt. Vernon, Illinois, which enabled the Company to distribute its portfolio of top-selling brands throughout the high-growth state. Illinois surpassed $1.6 billion in adult-use cannabis sales last year, and MariMed looks to continue expanding there as current regulations in Illinois permit operators to own up to 10 dispensaries. In addition to its expansion efforts in Illinois, MariMed has acquired the assets of Our Community Wellness & Compassionate Care Center in Prince George's County, Maryland. This acquisition marks MariMed's second adult-use Thrive Wellness dispensary in Maryland, complementing its existing location in Annapolis. The Company is vertically integrated in Maryland, with a cultivation and processing facility in Hagerstown that distributes MariMed products state-wide. As a company dedicated to developing and distributing great brands and delivering an exceptional customer experience at its retail stores, these recent acquisitions underscore MariMed's commitment to strategic expansion and enhancing its footprint in key cannabis markets. Contact Details Proactive North America Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com

April 24, 2024 02:01 PM Eastern Daylight Time

Video

Nevis Brands announces major shots are now for sale in dozens if dispensaries in Missouri

Nevis Brands

Nevis Brands CEO John Kueber joined Steve Darling from Proactive to announce the successful completion of the initial production run of Major shots in Missouri through its licensee, Stash House Distro. This milestone marks the expansion of Nevis Brands' product offerings into the Missouri market, with three flavors of its 2-ounce Major shots—Fruit Punch, Blackberry Lemonade, and Blueberry—now available for sale. Nevis Brands has previously introduced these products in Washington and Ohio, achieving successful distribution. The Major shots are infused with 100mg of THC and leverage a proprietary formula of flavor and emulsion technology, enabling rapid onset effects in under 20 minutes with minimal cannabis taste. The products are now accessible to consumers in numerous dispensaries across Missouri, further solidifying Nevis Brands' presence in the cannabis beverage market. Additionally, Kueber shared news regarding the restructuring of the company's Promissory Note due to SoRSE Technology Corp., which was initially part of Nevis Brands' purchase of the SoRSE Technology business units "THC Essentials," including the Major brand. Under the revised terms of the agreement, Nevis Brands will pay USD $100,000 by April 30th, 2024, and proceed with periodic payments to retire the note principal by December 31, 2024. This strategic move reflects Nevis Brands' commitment to managing its financial obligations while continuing to expand its product portfolio and market presence. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

April 24, 2024 01:57 PM Eastern Daylight Time

Video

1 ... 27 28 29 30 31 ... 249